| Ruxandra Oana Jadic, MD | |
|
560 Van Reed Rd, Suite 101, Wyomissing, PA 19610-1799 | |
| (484) 628-2525 | |
| (484) 628-2526 |
| Full Name | Ruxandra Oana Jadic |
|---|---|
| Gender | Female |
| Speciality | Geriatric Medicine |
| Experience | 36 Years |
| Location | 560 Van Reed Rd, Wyomissing, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134170053 | NPI | - | NPPES |
| 1023662990001 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0300X | Internal Medicine - Geriatric Medicine | MD438107 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Reading Hospital | West reading, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tower Health Medical Group | 7618889213 | 577 |
News Archive
Ranbaxy Pharmaceuticals, a wholly-owned subsidiary of Ranbaxy Laboratories Limited of New Delhi, India, announced today that RLL has received approval from the U. S. Food and Drug Administration to manufacture and market Loratadine and Pseudoephedrine Sulfate Extended Release Tablets
Elite Pharmaceuticals, Inc. announced today the acquisition of a currently approved Abbreviated New Drug Application (ANDA) for hydromorphone hydrochloride 8 mg tablets from Mikah Pharma LLC. The hydromorphone hydrochloride tablets are the generic equivalent of Dilaudid® 8 mg.
The VCU Life Sciences Survey is the first poll to reflect the discovery reported internationally in November that human skin cells can be used to create stem cells or their near equivalents.
Cardiovascular Systems, Inc. (CSI), has completed patient enrollment in its prospective, randomized CALCIUM 360° clinical trial, part of the company's 360° Clinical Series. The CALCIUM 360° feasibility study is evaluating the treatment of peripheral arterial disease (PAD) behind and below the knee using CSI's Diamondback 360® System, a minimally invasive catheter for treating PAD anywhere in the leg. Dr. Nicolas Shammas, an interventional cardiologist at Trinity Medical Center, Bettendorf, Iowa, is the study's principal investigator.
The Congressional Budget Office recently estimated that 30 million Americans still will be left without health insurance in 2022, after the U.S. Supreme Court ruling that largely upheld President Obama's healthcare plan. The part of the plan that was not upheld by the high court, however, contains the key to lowering that number.
› Verified 3 days ago
| Entity Name | Tower Health Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609291350 PECOS PAC ID: 7618889213 Enrollment ID: O20040311000072 |
News Archive
Ranbaxy Pharmaceuticals, a wholly-owned subsidiary of Ranbaxy Laboratories Limited of New Delhi, India, announced today that RLL has received approval from the U. S. Food and Drug Administration to manufacture and market Loratadine and Pseudoephedrine Sulfate Extended Release Tablets
Elite Pharmaceuticals, Inc. announced today the acquisition of a currently approved Abbreviated New Drug Application (ANDA) for hydromorphone hydrochloride 8 mg tablets from Mikah Pharma LLC. The hydromorphone hydrochloride tablets are the generic equivalent of Dilaudid® 8 mg.
The VCU Life Sciences Survey is the first poll to reflect the discovery reported internationally in November that human skin cells can be used to create stem cells or their near equivalents.
Cardiovascular Systems, Inc. (CSI), has completed patient enrollment in its prospective, randomized CALCIUM 360° clinical trial, part of the company's 360° Clinical Series. The CALCIUM 360° feasibility study is evaluating the treatment of peripheral arterial disease (PAD) behind and below the knee using CSI's Diamondback 360® System, a minimally invasive catheter for treating PAD anywhere in the leg. Dr. Nicolas Shammas, an interventional cardiologist at Trinity Medical Center, Bettendorf, Iowa, is the study's principal investigator.
The Congressional Budget Office recently estimated that 30 million Americans still will be left without health insurance in 2022, after the U.S. Supreme Court ruling that largely upheld President Obama's healthcare plan. The part of the plan that was not upheld by the high court, however, contains the key to lowering that number.
› Verified 3 days ago
| Entity Name | Reading Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992387518 PECOS PAC ID: 7618886490 Enrollment ID: O20040408001076 |
News Archive
Ranbaxy Pharmaceuticals, a wholly-owned subsidiary of Ranbaxy Laboratories Limited of New Delhi, India, announced today that RLL has received approval from the U. S. Food and Drug Administration to manufacture and market Loratadine and Pseudoephedrine Sulfate Extended Release Tablets
Elite Pharmaceuticals, Inc. announced today the acquisition of a currently approved Abbreviated New Drug Application (ANDA) for hydromorphone hydrochloride 8 mg tablets from Mikah Pharma LLC. The hydromorphone hydrochloride tablets are the generic equivalent of Dilaudid® 8 mg.
The VCU Life Sciences Survey is the first poll to reflect the discovery reported internationally in November that human skin cells can be used to create stem cells or their near equivalents.
Cardiovascular Systems, Inc. (CSI), has completed patient enrollment in its prospective, randomized CALCIUM 360° clinical trial, part of the company's 360° Clinical Series. The CALCIUM 360° feasibility study is evaluating the treatment of peripheral arterial disease (PAD) behind and below the knee using CSI's Diamondback 360® System, a minimally invasive catheter for treating PAD anywhere in the leg. Dr. Nicolas Shammas, an interventional cardiologist at Trinity Medical Center, Bettendorf, Iowa, is the study's principal investigator.
The Congressional Budget Office recently estimated that 30 million Americans still will be left without health insurance in 2022, after the U.S. Supreme Court ruling that largely upheld President Obama's healthcare plan. The part of the plan that was not upheld by the high court, however, contains the key to lowering that number.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ruxandra Oana Jadic, MD 560 Van Reed Rd, Suite 101, Wyomissing, PA 19610-1799 Ph: (484) 628-2525 | Ruxandra Oana Jadic, MD 560 Van Reed Rd, Suite 101, Wyomissing, PA 19610-1799 Ph: (484) 628-2525 |
News Archive
Ranbaxy Pharmaceuticals, a wholly-owned subsidiary of Ranbaxy Laboratories Limited of New Delhi, India, announced today that RLL has received approval from the U. S. Food and Drug Administration to manufacture and market Loratadine and Pseudoephedrine Sulfate Extended Release Tablets
Elite Pharmaceuticals, Inc. announced today the acquisition of a currently approved Abbreviated New Drug Application (ANDA) for hydromorphone hydrochloride 8 mg tablets from Mikah Pharma LLC. The hydromorphone hydrochloride tablets are the generic equivalent of Dilaudid® 8 mg.
The VCU Life Sciences Survey is the first poll to reflect the discovery reported internationally in November that human skin cells can be used to create stem cells or their near equivalents.
Cardiovascular Systems, Inc. (CSI), has completed patient enrollment in its prospective, randomized CALCIUM 360° clinical trial, part of the company's 360° Clinical Series. The CALCIUM 360° feasibility study is evaluating the treatment of peripheral arterial disease (PAD) behind and below the knee using CSI's Diamondback 360® System, a minimally invasive catheter for treating PAD anywhere in the leg. Dr. Nicolas Shammas, an interventional cardiologist at Trinity Medical Center, Bettendorf, Iowa, is the study's principal investigator.
The Congressional Budget Office recently estimated that 30 million Americans still will be left without health insurance in 2022, after the U.S. Supreme Court ruling that largely upheld President Obama's healthcare plan. The part of the plan that was not upheld by the high court, however, contains the key to lowering that number.
› Verified 3 days ago
Nirav R. Shah, MD, MPH Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 1011 Reed Ave, Suite 300, Wyomissing, PA 19610 Phone: 610-374-4401 Fax: 610-374-7140 | |
Dr. David F Steffy, M.D. Geriatric Medicine Medicare: Not Enrolled in Medicare Practice Location: 950b N Wyomissing Blvd, 3rd Floor, Wyomissing, PA 19610 Phone: 610-898-1820 Fax: 610-372-0164 | |
Dr. Michael Bernard Russo, M.D. Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 2605 Keiser Blvd, Wyomissing, PA 19610 Phone: 610-685-8500 Fax: 610-685-4833 | |
Dr. Pallak Agarwal, MD Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 2608 Keiser Blvd, Wyomissing, PA 19610 Phone: 610-685-5864 Fax: 610-929-1528 | |
Dr. Kristie Marie Pepper, D.O. Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 2760 Century Blvd, Wyomissing, PA 19610 Phone: 610-375-4251 Fax: 610-685-2870 | |
Louis La Luna, M.D. Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 1011 Reed Ave, Suite 300, Wyomissing, PA 19610 Phone: 610-374-4401 Fax: 610-374-7140 | |
Tara Lynn Dimino, MD Geriatric Medicine Medicare: Not Enrolled in Medicare Practice Location: 2605 Keiser Blvd, Wyomissing, PA 19610 Phone: 610-685-8500 Fax: 610-685-4833 |